Security
Silence Therapeutics Plc American Depository Share · SLN
SLNNASDAQotherCurrentCIK 1479615Updated Oct 20, 2026
SLN price & chart
Loading TradingView…
NASDAQ:SLN on TradingView ↗About the company
Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNA therapies designed to precisely target and silence genes that cause disease. The Company is advancing a growing pipeline of siRNA product candidates targeting areas of high unmet need across rare and common diseases where treatments are limited or inadequate. For more information, please visit https://www.silence-therapeutics.com/.
In the news
Recent filings
DEFA14A filing
DEFA14A filing
Entry into a Material Definitive Agreement · Regulation FD Disclosure
Items 1.01, 7.01, 9.01
SCHEDULE 13D/A - filed by Griffiths Richard Ian regarding Silence Therapeutics plc
Entry into a Material Definitive Agreement · Other Events
Items 1.01, 8.01, 9.01
Show 5 more recent filings
424B5 filing
S-3MEF filing
424B5 filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
10-Q filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 146,790,000Source | — | 106,412,000Source | 165,233,000Source | — | 115,123,000Source | 185,298,000Source | — | 131,442,000Source | 202,635,000Source | — | — |
| Property, Plant and Equipment, NetUSD | 1,655,000Source | — | 1,325,000Source | 1,775,000Source | — | 1,396,000Source | 1,693,000Source | — | 1,581,000Source | 1,818,000Source | — | — |
| GoodwillUSD | 10,612,000Source | 9,392,000Source | 10,325,000Source | 10,621,000Source | — | 10,358,000Source | 10,621,000Source | 9,760,000Source | 10,621,000Source | 9,392,000Source | 7,840,000Source | 8,009,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | 288,000Source | — | — | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 82,031,000Source | — | 72,054,000Source | 41,739,000Source | — | 5,657,000Source | 64,886,000Source | — | 11,277,000Source | 121,330,000Source | — | — |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 28,000Source | — | — | 85,000Source | — | 0Source | 41,000Source | — | 0Source | 972,000Source | — | — |
| Assets, CurrentUSD | 133,632,000Source | — | 94,281,000Source | 148,553,000Source | — | 102,852,000Source | 169,790,000Source | — | 118,658,000Source | 187,366,000Source | — | — |
| Operating Lease, Right-of-Use AssetUSD | 192,000Source | — | 117,000Source | 58,000Source | — | 142,000Source | 107,000Source | — | 167,000Source | 157,000Source | — | — |
| Other Assets, NoncurrentUSD | 399,000Source | — | 127,000Source | 3,913,000Source | — | 127,000Source | 3,614,000Source | — | 127,000Source | 3,590,000Source | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 72,727,000Source | — | 67,941,000Source | 71,078,000Source | — | 65,721,000Source | 72,555,000Source | — | 69,138,000Source | 68,612,000Source | — | — |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 10,290,000Source | — | 10,292,000Source | 10,290,000Source | — | 10,290,000Source | 10,289,000Source | — | 10,290,000Source | 10,288,000Source | — | — |
| Retained Earnings (Accumulated Deficit)USD | -550,802,000Source | — | -589,632,000Source | -529,844,000Source | — | -577,526,000Source | -502,536,000Source | — | -562,572,000Source | -474,044,000Source | — | — |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -3,073,000Source | — | -3,341,000Source | -1,404,000Source | — | -3,368,000Source | -8,084,000Source | — | -2,976,000Source | -11,781,000Source | — | — |
| Stockholders' Equity Attributable to ParentUSD | 74,063,000Source | 126,696,000Source | 38,471,000Source | 94,155,000Source | 142,527,000Source | 49,402,000Source | 112,743,000Source | 156,762,000Source | 62,304,000Source | 134,023,000Source | — | — |
| Additional Paid in Capital, Common StockUSD | 617,648,000Source | — | 621,152,000Source | 615,113,000Source | — | 620,006,000Source | 613,074,000Source | — | 617,562,000Source | 609,560,000Source | — | — |
| Liabilities and EquityUSD | 146,790,000Source | — | 106,412,000Source | 165,233,000Source | — | 115,123,000Source | 185,298,000Source | — | 131,442,000Source | 202,635,000Source | — | — |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 17,379,000Source | — | 12,714,000Source | 14,768,000Source | — | 10,460,000Source | 19,264,000Source | — | 13,613,000Source | 16,822,000Source | — | — |
| Operating Lease, Liability, CurrentUSD | 85,000Source | — | 103,000Source | 0Source | — | 93,000Source | 60,000Source | — | 89,000Source | 117,000Source | — | — |
| Operating Lease, Liability, NoncurrentUSD | 97,000Source | — | 9,000Source | — | — | 43,000Source | — | — | 71,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 102,200,000Source | — | 72,100,000Source | 114,200,000Source | — | 70,100,000Source | 136,500,000Source | — | 85,100,000Source | 147,300,000Source | — | — |
| CurrentTaxAssetsCurrentGBP | — | — | — | — | — | — | — | — | — | — | 17,627,000Source | 14,882,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | — | — |
| IssuedCapitalGBP | — | — | — | — | — | — | — | — | — | — | 5,942,000Source | 5,390,000Source |
| Short-term InvestmentsUSD | 20,161,000Source | — | 0Source | 72,416,000Source | — | 64,421,000Source | 71,648,000Source | — | 73,837,000Source | 26,004,000Source | — | — |
| TradeAndOtherCurrentPayablesGBP | — | — | — | — | — | — | — | — | — | — | 12,429,000Source | 12,633,000Source |
| TradeAndOtherPayablesGBP | — | — | — | — | — | — | — | — | — | — | 12,429,000Source | 12,633,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -14,957,000Source | -28,530,000Source | -88,612,000Source | -45,309,000Source | -43,267,000Source | -40,489,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 2,447,000Source | 3,540,000Source | 8,074,000Source | 16,307,000Source | — | — |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 0Source | -940,000Source | -1,024,000Source | 904,000Source | — | — |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | 0Source | 11,000Source | 845,000Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -15,603,000Source | -12,309,000Source | -62,271,000Source | -67,640,000Source | — | — |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 10,000,000Source | -44,381,000Source | -47,992,000Source | -21,966,000Source | — | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 0Source | 4,000Source | 55,000Source | 211,000Source | — | — |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 0Source | 14,000Source | 15,000Source | 142,087,000Source | — | — |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | -88,000Source | -76,000Source | 637,000Source | -433,000Source | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -17,000Source | 232,000Source | 195,000Source | 60,000Source | — | — |
| Additional Financial Items | ||||||||||||
| AmortizationUSD | — | — | — | — | — | — | 34,000Source | 65,000Source | 243,000Source | 257,000Source | — | — |
| AdjustmentsForCurrentTaxOfPriorPeriodGBP | — | — | — | — | — | — | — | — | — | — | -15,000Source | 401,000Source |
| AdjustmentsForFinanceCostsGBP | — | — | — | — | — | — | — | — | — | — | 2,152,000Source | — |
| AdjustmentsForFinanceIncomeGBP | — | — | — | — | — | — | — | — | — | — | 1,446,000Source | 1,272,000Source |
| AdjustmentsForSharebasedPaymentsGBP | — | — | — | — | — | — | — | — | — | — | 13,050,000Source | 10,252,000Source |
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | — | — | 8,074,000Source | 16,307,000Source | — | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 102,200,000Source | — | 72,100,000Source | 114,200,000Source | 70,100,000Source | 136,500,000Source | 85,100,000Source | 147,300,000Source | — | — |
| DepreciationUSD | — | — | — | — | — | — | 72,000Source | 73,000Source | 312,000Source | 336,000Source | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 1,934,000Source | -11,396,000Source | 151,000Source | -6,613,000Source | -482,000Source | -3,769,000Source | -8,467,000Source | 646,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 5,795,000Source | 7,697,000Source | 4,717,000Source | 5,131,000Source | 7,026,000Source | 7,684,000Source | 22,344,000Source | 26,884,000Source | 20,636,000Source | 19,609,000Source |
| GoodwillUSD | — | — | 10,612,000Source | 9,392,000Source | 10,325,000Source | 10,621,000Source | 10,358,000Source | 10,621,000Source | 10,621,000Source | 9,392,000Source | 7,840,000Source | 8,009,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | — | — |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | 1,000Source | 49,000Source | 1,000Source | 10,000Source | 0Source | 0Source | 11,000Source | 845,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -20,958,000Source | -35,544,000Source | -12,268,000Source | -27,354,000Source | -14,957,000Source | -28,530,000Source | -88,612,000Source | -45,309,000Source | — | — |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesGBP | — | — | — | — | — | — | — | — | — | — | 174,000Source | 190,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 0Source | 14,000Source | 15,000Source | 142,087,000Source | — | — |
| ProceedsFromIssuingSharesGBP | — | — | — | — | — | — | — | — | — | — | 25,329,000Source | 43,239,000Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesGBP | — | — | — | — | — | — | — | — | — | — | — | 300,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 159,000Source | 1,498,000Source | 0Source | 224,000Source | 422,000Source | 142,000Source | 559,000Source | 43,258,000Source | — | — |
| Cost of RevenueUSD | — | — | 64,000Source | 3,639,000Source | 0Source | 85,000Source | 11,000Source | 54,000Source | 215,000Source | 11,810,000Source | 10,318,000Source | 10,880,000Source |
| Operating Income (Loss)USD | — | — | -26,244,000Source | -29,997,000Source | -13,865,000Source | -23,963,000Source | -15,737,000Source | -28,409,000Source | -91,077,000Source | -63,319,000Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -20,957,000Source | -35,495,000Source | -12,267,000Source | -27,344,000Source | -14,957,000Source | -28,530,000Source | -88,601,000Source | -44,464,000Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | 1,000Source | 49,000Source | 1,000Source | 10,000Source | 0Source | 0Source | 11,000Source | 845,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -20,958,000Source | -35,544,000Source | -12,268,000Source | -27,354,000Source | -14,957,000Source | -28,530,000Source | -88,612,000Source | -45,309,000Source | — | — |
| Earnings Per Share, BasicUSD per share | — | — | -0.15Source | -0.25Source | -0.09Source | -0.19Source | -0.11Source | -0.2Source | -0.63Source | -0.33Source | — | — |
| Earnings Per Share, DilutedUSD per share | — | — | -0.15Source | -0.25Source | -0.09Source | -0.19Source | -0.11Source | -0.2Source | -0.63Source | -0.33Source | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 141,701,848Source | 141,198,163Source | 141,709,762Source | 141,696,047Source | 141,702,578Source | 141,678,734Source | 141,694,702Source | 138,752,224Source | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 141,701,848Source | 141,198,163Source | 141,709,762Source | 141,696,047Source | 141,702,578Source | 141,678,734Source | 141,694,702Source | 138,752,224Source | — | — |
| Additional Financial Items | ||||||||||||
| ApplicableTaxRatenumber | — | — | — | — | — | — | — | — | — | — | 0.25Source | 0.19Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 11,000Source | 845,000Source | — | — |
| CurrentTaxExpenseIncomeGBP | — | — | — | — | — | — | — | — | — | — | -7,028,000Source | -7,280,000Source |
| DeferredTaxExpenseIncomeGBP | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| EmployeeBenefitsExpenseGBP | — | — | — | — | — | — | — | — | — | — | 30,426,000Source | 26,875,000Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesGBP | — | — | — | — | — | — | — | — | — | — | 13,050,000Source | 10,252,000Source |
| FinanceCostsGBP | — | — | — | — | — | — | — | — | — | — | 2,152,000Source | 47,000Source |
| FinanceIncomeGBP | — | — | — | — | — | — | — | — | — | — | 1,446,000Source | 1,272,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 1,934,000Source | -11,396,000Source | 151,000Source | -6,613,000Source | -482,000Source | -3,769,000Source | -8,467,000Source | 646,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 5,795,000Source | 7,697,000Source | 4,717,000Source | 5,131,000Source | 7,026,000Source | 7,684,000Source | 22,344,000Source | 26,884,000Source | 20,636,000Source | 19,609,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | — | — |
| Gross ProfitUSD | — | — | 95,000Source | -2,141,000Source | 0Source | 139,000Source | 411,000Source | 88,000Source | 344,000Source | 31,448,000Source | 15,057,000Source | 6,621,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -89,679,000Source | — | — | — |
| IncomeTaxExpenseContinuingOperationsGBP | — | — | — | — | — | — | — | — | — | — | -7,043,000Source | -6,879,000Source |
| InterestExpenseOnLeaseLiabilitiesGBP | — | — | — | — | — | — | — | — | — | — | 34,000Source | 47,000Source |
| NetForeignExchangeLossGBP | — | — | — | — | — | — | — | — | — | — | 2,118,000Source | — |
| Other IncomeUSD | — | — | — | — | — | — | 519,000Source | 969,000Source | 3,480,000Source | 4,472,000Source | — | — |
| ProfitLossBeforeTaxGBP | — | — | — | — | — | — | — | — | — | — | -50,310,000Source | -47,368,000Source |
| ProfitLossFromOperatingActivitiesGBP | — | — | — | — | — | — | — | — | — | — | -49,604,000Source | -48,593,000Source |
| Research and Development ExpenseUSD | — | — | 20,544,000Source | 20,159,000Source | 9,148,000Source | 17,647,000Source | 9,122,000Source | 20,813,000Source | 67,753,000Source | 67,883,000Source | 44,025,000Source | 35,605,000Source |
Offerings
Registration 333-298248
Registration 333-295992
Filing attachments
d189864dex991.htm · DEFA14A · 2026-10-19
Exhibit 99.1 Employee Letter Subject: Silence Therapeutics’ Next Chapter Dear Silence Colleagues, I’m reaching out to share the exciting news that we have entered into an agreement to be acquired by Merck KGaA, Darmstadt, Germany in a transaction with an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion. This agreement is the result of a competitive sale process and careful consideration by our Board of Directors and management team. As you may know, Merck K…
Read attachment ↗d189864dex992.htm · DEFA14A · 2026-10-19
Exhibit 99.2 Employee FAQ What was announced? ─────────────────────── We have entered into an agreement under which Merck KGaA, Darmstadt, Germany has agreed to acquire Silence Therapeutics in an all-cash transaction with an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion. This agreement with Merck KGaA, Darmstadt, Germany follows a competitive sale process and careful consideration by our Board of Directors and management team. In Merck KGaA,…
Read attachment ↗d172259dex991.htm · 8-K · 2026-10-19
Exhibit 99.1 Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany All-Cash Transaction Values Silence Therapeutics at Approximately $1.3 Billion Price of$20.00 Per ADS in Cash Represents 130% Premium to Silence’s Closing ADS Price on October 16, 2026 Transaction Delivers Significant, Immediate and Certain Cash Value to Silence Shareholders and ADS Holders LONDON, UK, October 19, 2026 - Silence Therapeutics plc (Nasdaq: SLN) (“Silence”), a biotechnolog…
Read attachment ↗tm2623118d1_ex99-1.htm · SCHEDULE 13D/A · 2026-08-13
Exhibit 99.1 Schedule 1 Transactions in ADSs past 60 days to 13 August 2026 Date Nature of the Reporting Person Amount of Securities Price Transaction Purchased/Sold ───────────────────────────────────────────────────────────────────────────────────────────── 08/10/26 Sale Richard Griffiths 2,792,826 $ 16.00 08/10/26 Sale Richard Griffiths …
Read attachment ↗d168365dex991.htm · 8-K · 2026-08-12
EX-99.1 4 d168365dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares 2026-08-10 LONDON - (BUSINESS WIRE) - Silence Therapeutics plc (“Silence” or the “Company”), a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) therapies, today announced that it has commenced an underwritten public offering of approximately $150 million of its American Depositary Shares …
Read attachment ↗d168365dex992.htm · 8-K · 2026-08-12
EX-99.2 5 d168365dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering August 11, 2026 LONDON, Silence Therapeutics plc (“Silence” or the “Company”), a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) therapies, today announced that it has priced its previously announced underwritten public offering of 12,962,963 American Depositary Shares (“ADSs”), each representing …
Read attachment ↗